Large Molecule Drug Discovery Outsourcing Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Large Molecule Drug Discovery Outsourcing Market 

5.1. COVID-19 Landscape: Large Molecule Drug Discovery Outsourcing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Large Molecule Drug Discovery Outsourcing Market, By Molecule Type

8.1. Large Molecule Drug Discovery Outsourcing Market, by Molecule Type

8.1.1. Monoclonal Antibodies (mAbs)

8.1.1.1. Market Revenue and Forecast

8.1.2. Recombinant Proteins

8.1.2.1. Market Revenue and Forecast

8.1.3. Peptides & Polypeptides

8.1.3.1. Market Revenue and Forecast

8.1.4. Antibody-Drug Conjugates (ADCs)

8.1.4.1. Market Revenue and Forecast

8.1.5. Bispecific Antibodies

8.1.5.1. Market Revenue and Forecast

Chapter 9. Global Large Molecule Drug Discovery Outsourcing Market, By Service Type

9.1. Large Molecule Drug Discovery Outsourcing Market, by Service Type

9.1.1. Target Identification & Validation

9.1.1.1. Market Revenue and Forecast

9.1.2. Antibody Engineering & Humanization

9.1.2.1. Market Revenue and Forecast

9.1.3. Protein Expression & Purification

9.1.3.1. Market Revenue and Forecast

9.1.4. Assay Development & Screening

9.1.4.1. Market Revenue and Forecast

9.1.5. Lead Identification & Optimization

9.1.5.1. Market Revenue and Forecast

Chapter 10. Global Large Molecule Drug Discovery Outsourcing Market, By Technology Platform 

10.1. Large Molecule Drug Discovery Outsourcing Market, by Technology Platform

10.1.1. Hybridoma Technology

10.1.1.1. Market Revenue and Forecast

10.1.2. Phage Display

10.1.2.1. Market Revenue and Forecast

10.1.3. Yeast Display

10.1.3.1. Market Revenue and Forecast

10.1.4. Mammalian Cell Expression Systems

10.1.4.1. Market Revenue and Forecast

10.1.5. Single-Cell Screening Platforms

10.1.5.1. Market Revenue and Forecast

Chapter 11. Global Large Molecule Drug Discovery Outsourcing Market, By End-User

11.1. Large Molecule Drug Discovery Outsourcing Market, by End-User

11.1.1. Large Biopharmaceutical Companies

11.1.1.1. Market Revenue and Forecast

11.1.2. Small & Mid-Sized Biotech Companies

11.1.2.1. Market Revenue and Forecast

11.1.3. Virtual / Emerging Biotech Firms

11.1.3.1. Market Revenue and Forecast

11.1.4. Academic & Research Institutes

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Large Molecule Drug Discovery Outsourcing Market, By Therapeutic Area

12.1. Large Molecule Drug Discovery Outsourcing Market, by Therapeutic Area

12.1.1. Oncology

12.1.1.1. Market Revenue and Forecast

12.1.2. Immunology & Inflammation

12.1.2.1. Market Revenue and Forecast

12.1.3. Infectious Diseases

12.1.3.1. Market Revenue and Forecast

12.1.4. Neurology

12.1.4.1. Market Revenue and Forecast

12.1.5. Cardiovascular Disorders

12.1.5.1. Market Revenue and Forecast

Chapter 13. Global Large Molecule Drug Discovery Outsourcing Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Molecule Type

13.1.2. Market Revenue and Forecast, by Service Type

13.1.3. Market Revenue and Forecast, by Technology Platform

13.1.4. Market Revenue and Forecast, by End-User

13.1.5. Market Revenue and Forecast, by Therapeutic Area

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Molecule Type

13.1.6.2. Market Revenue and Forecast, by Service Type

13.1.6.3. Market Revenue and Forecast, by Technology Platform

13.1.6.4. Market Revenue and Forecast, by End-User

13.1.6.5. Market Revenue and Forecast, by Therapeutic Area  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Molecule Type

13.1.7.2. Market Revenue and Forecast, by Service Type

13.1.7.3. Market Revenue and Forecast, by Technology Platform

13.1.7.4. Market Revenue and Forecast, by End-User

13.1.7.5. Market Revenue and Forecast, by Therapeutic Area

13.2. Europe

13.2.1. Market Revenue and Forecast, by Molecule Type

13.2.2. Market Revenue and Forecast, by Service Type

13.2.3. Market Revenue and Forecast, by Technology Platform

13.2.4. Market Revenue and Forecast, by End-User  

13.2.5. Market Revenue and Forecast, by Therapeutic Area  

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Molecule Type

13.2.6.2. Market Revenue and Forecast, by Service Type

13.2.6.3. Market Revenue and Forecast, by Technology Platform

13.2.7. Market Revenue and Forecast, by End-User  

13.2.8. Market Revenue and Forecast, by Therapeutic Area  

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Molecule Type

13.2.9.2. Market Revenue and Forecast, by Service Type

13.2.9.3. Market Revenue and Forecast, by Technology Platform

13.2.10. Market Revenue and Forecast, by End-User

13.2.11. Market Revenue and Forecast, by Therapeutic Area

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Molecule Type

13.2.12.2. Market Revenue and Forecast, by Service Type

13.2.12.3. Market Revenue and Forecast, by Technology Platform

13.2.12.4. Market Revenue and Forecast, by End-User

13.2.13. Market Revenue and Forecast, by Therapeutic Area

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Molecule Type

13.2.14.2. Market Revenue and Forecast, by Service Type

13.2.14.3. Market Revenue and Forecast, by Technology Platform

13.2.14.4. Market Revenue and Forecast, by End-User

13.2.15. Market Revenue and Forecast, by Therapeutic Area

13.3. APAC

13.3.1. Market Revenue and Forecast, by Molecule Type

13.3.2. Market Revenue and Forecast, by Service Type

13.3.3. Market Revenue and Forecast, by Technology Platform

13.3.4. Market Revenue and Forecast, by End-User

13.3.5. Market Revenue and Forecast, by Therapeutic Area

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Molecule Type

13.3.6.2. Market Revenue and Forecast, by Service Type

13.3.6.3. Market Revenue and Forecast, by Technology Platform

13.3.6.4. Market Revenue and Forecast, by End-User

13.3.7. Market Revenue and Forecast, by Therapeutic Area

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Molecule Type

13.3.8.2. Market Revenue and Forecast, by Service Type

13.3.8.3. Market Revenue and Forecast, by Technology Platform

13.3.8.4. Market Revenue and Forecast, by End-User

13.3.9. Market Revenue and Forecast, by Therapeutic Area

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Molecule Type

13.3.10.2. Market Revenue and Forecast, by Service Type

13.3.10.3. Market Revenue and Forecast, by Technology Platform

13.3.10.4. Market Revenue and Forecast, by End-User

13.3.10.5. Market Revenue and Forecast, by Therapeutic Area

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Molecule Type

13.3.11.2. Market Revenue and Forecast, by Service Type

13.3.11.3. Market Revenue and Forecast, by Technology Platform

13.3.11.4. Market Revenue and Forecast, by End-User

13.3.11.5. Market Revenue and Forecast, by Therapeutic Area

13.4. MEA

13.4.1. Market Revenue and Forecast, by Molecule Type

13.4.2. Market Revenue and Forecast, by Service Type

13.4.3. Market Revenue and Forecast, by Technology Platform

13.4.4. Market Revenue and Forecast, by End-User

13.4.5. Market Revenue and Forecast, by Therapeutic Area

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Molecule Type

13.4.6.2. Market Revenue and Forecast, by Service Type

13.4.6.3. Market Revenue and Forecast, by Technology Platform

13.4.6.4. Market Revenue and Forecast, by End-User

13.4.7. Market Revenue and Forecast, by Therapeutic Area

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Molecule Type

13.4.8.2. Market Revenue and Forecast, by Service Type

13.4.8.3. Market Revenue and Forecast, by Technology Platform

13.4.8.4. Market Revenue and Forecast, by End-User

13.4.9. Market Revenue and Forecast, by Therapeutic Area

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Molecule Type

13.4.10.2. Market Revenue and Forecast, by Service Type

13.4.10.3. Market Revenue and Forecast, by Technology Platform

13.4.10.4. Market Revenue and Forecast, by End-User

13.4.10.5. Market Revenue and Forecast, by Therapeutic Area

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Molecule Type

13.4.11.2. Market Revenue and Forecast, by Service Type

13.4.11.3. Market Revenue and Forecast, by Technology Platform

13.4.11.4. Market Revenue and Forecast, by End-User

13.4.11.5. Market Revenue and Forecast, by Therapeutic Area

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Molecule Type

13.5.2. Market Revenue and Forecast, by Service Type

13.5.3. Market Revenue and Forecast, by Technology Platform

13.5.4. Market Revenue and Forecast, by End-User

13.5.5. Market Revenue and Forecast, by Therapeutic Area

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Molecule Type

13.5.6.2. Market Revenue and Forecast, by Service Type

13.5.6.3. Market Revenue and Forecast, by Technology Platform

13.5.6.4. Market Revenue and Forecast, by End-User

13.5.7. Market Revenue and Forecast, by Therapeutic Area

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Molecule Type

13.5.8.2. Market Revenue and Forecast, by Service Type

13.5.8.3. Market Revenue and Forecast, by Technology Platform

13.5.8.4. Market Revenue and Forecast, by End-User

13.5.8.5. Market Revenue and Forecast, by Therapeutic Area

Chapter 14. Company Profiles

14.1. Charles River Laboratories International, Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Dalton Pharma Services

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Domainex Ltd.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Eurofins Scientific SE

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Evotec SE

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. GenScript Biotech Corporation

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Jubilant Biosys Limited

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Laboratory Corporation of America Holdings (Covance)

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Merck & Co., Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Pharmaceutical Product Development, LLC

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms